Schizophrenia: trials for referral
549 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 549 open trials.
Phase 31 site
RecruitingChina
NCT07918222
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
Shanghai Mental Health Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT06138054
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
VA Office of Research and Development
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT06336382
Tau Biomarkers in Late-onset Psychosis (LOP)
Jeremy Koppel
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 339 sites
RecruitingBulgaria, Czechia, Germany, Spain, France, Croatia
2024-519836-18-00
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
Newron Pharmaceuticals S.p.A.
Registry updated 4 Nov 2026
Registry record: EU CTISNo phase1 site
RecruitingUnited States
NCT07006935
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Case Western Reserve University
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingChina
NCT07911787
Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07913100
Real-World Impact of TV-44749 in Adults With Schizophrenia
Teva Branded Pharmaceutical Products R&D LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 365 sites
RecruitingColombia, Serbia, United States
NCT06229210
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 271 sites
RecruitingBulgaria, Czechia, Spain, Croatia, Italy, Poland
NCT06540833
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 18 sites
RecruitingUnited States
NCT07615426
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingUnited States
NCT07788755
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
University of Minnesota
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingDenmark
2024-519389-28-00
Acute Effects of Partial GABA(A)-Receptor Modulation by GT-002 on Psychophysiological Measures: The TOTEMS Phase II Clinical Trial Targeting Cognitive Impairment Associated with Schizophrenia
Region Hovedstadens Psykiatriske
Registry updated 2 Nov 2026
Registry record: EU CTISNo phase68 sites
RecruitingUnited States
NCT07379827
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Bristol-Myers Squibb
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07908680
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
Novartis Pharmaceuticals
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
Not yet recruitingChina
NCT07815210
Phase I Trial of HHK101 in Patients With Schizophrenia
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 356 sites
RecruitingJapan
NCT06882785
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Bristol-Myers Squibb
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingCanada
NCT06672588
Magnetic Seizure Therapy for Schizophrenia - Trial
Centre for Addiction and Mental Health
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT07743645
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
The University of Texas Health Science Center, Houston
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingUnited States
NCT07680946
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
TG Therapeutics, Inc.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 352 sites
RecruitingArgentina, Bulgaria, Czechia, Denmark, Spain, Poland
NCT07686263
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingUnited States
NCT07898631
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
Butler Hospital
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingCanada
NCT07902518
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
Ciusss de L'Est de l'Île de Montréal
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07701343
tACS for Working Memory in Schizophrenia
Central South University
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07805980
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Second Xiangya Hospital of Central South University
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT05389787
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Northwell Health
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingUnited States
NCT07900893
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
Washington University School of Medicine
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07795554
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Second Xiangya Hospital of Central South University
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 3278 sites
RecruitingArgentina, Belgium, Bulgaria, Brazil, China, Germany
NCT06585787
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingUnited States
NCT07897266
Non-Invasive Vagus Nerve Stimulation as a Probe to Map Functional Connectivity in Schizophrenia Using Functional Magnetic Resonance Imaging
University of Alabama at Birmingham
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruiting
NCT07898852
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
Dokuz Eylul University
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States152 open trials
- France47 open trials
- China41 open trials
- Canada27 open trials
- United Kingdom18 open trials
- Taiwan15 open trials
- Romania14 open trials
- Bulgaria13 open trials
- Spain13 open trials
- Germany13 open trials
- Poland13 open trials
- Denmark12 open trials
- India10 open trials
- Italy9 open trials
- Serbia8 open trials
- Japan8 open trials
- Netherlands8 open trials
- Hungary7 open trials
- Argentina7 open trials
- Israel7 open trials
- Czechia6 open trials
- Austria6 open trials
- Switzerland6 open trials
- Slovakia5 open trials
- Hong Kong SAR China5 open trials
- Croatia4 open trials
- Colombia4 open trials
- Portugal4 open trials
- Norway4 open trials
- South Korea3 open trials
- Puerto Rico3 open trials
- Australia3 open trials
- Greece3 open trials
- Brazil3 open trials
- Belgium2 open trials
- Sweden2 open trials
- Mexico2 open trials
- Ireland2 open trials
- Ukraine1 open trials
- Bahrain1 open trials
- Finland1 open trials
- Chile1 open trials
- Tunisia1 open trials
- Malaysia1 open trials
- Ghana1 open trials
- Indonesia1 open trials
- Egypt1 open trials
- Singapore1 open trials
- Guadeloupe1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
3 trials · 60 publications · ROR
Center for Translational Research in Neuroimaging and Data Science
Atlanta, United States
0 trials · 135 publications · ROR
Centro de Investigación Biomédica en Red de Salud Mental
Madrid, Spain
0 trials · 425 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 75 publications · ROR
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Barcelona, Spain
0 trials · 139 publications · ROR
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, United States
0 trials · 199 publications · ROR
Florey Institute of Neuroscience and Mental Health
Melbourne, Australia
0 trials · 76 publications · ROR
Nathan Kline Institute for Psychiatric Research
Orangeburg, United States
0 trials · 62 publications · ROR
National Institute of Mental Health and Neurosciences
Bengaluru, India
0 trials · 125 publications · ROR
Rutgers, The State University of New Jersey
New Brunswick, United States
0 trials · 96 publications · ROR
South London and Maudsley NHS Foundation Trust
London, United Kingdom
5 trials · 205 publications · ROR
The University of Texas Health Science Center at Houston
Houston, United States
6 trials · 78 publications · ROR
University of California, San Francisco
San Francisco, United States
2 trials · 141 publications · ROR
University of Electronic Science and Technology of China
Chengdu, China
0 trials · 110 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
3 trials · 195 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
NCT07918222 · Phase 3 · China
Source: ClinicalTrials.govOpened for recruitment
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 · Phase 3 · Argentina, Bulgaria, Czechia, Denmark, Spain, Poland
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660 · Phase 2 · Bulgaria, Czechia, France, Hungary, Italy, Poland
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT06315972 · Phase 2 · Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
NCT05622201 · Phase 2 · Sweden
Source: ClinicalTrials.govOpened for recruitment
NCT03817502 · Phase 3 · Bulgaria, Colombia, Mexico, Romania, Serbia, Russia
Source: ClinicalTrials.govClosed for recruitment
NCT03817502 · Phase 3 · Bulgaria, Colombia, Mexico, Romania, Serbia, Russia
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 · Phase 3 · Argentina, Bulgaria, Czechia, Denmark, Spain, Poland
Source: ClinicalTrials.govClosed for recruitment
California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis
NCT04007510 · No phase · United States
Source: ClinicalTrials.govNew in the registry
Mindfulness-Integrated Psychoeducation for Patients With Schizophrenia
NCT07917520 · No phase · Egypt
Source: ClinicalTrials.govNew in the registry
Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia
NCT07917637 · No phase · Indonesia
Source: ClinicalTrials.govPhase changed: No phase → Phase 4
NCT05656469 · Phase 4 · Germany, Spain, United Kingdom, Netherlands, Romania, Serbia
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Randomised trial
The primary care companion for CNS disorders · PubMed
Meta-analysis
Schizophrenia bulletin · PubMed
Randomised trial
International journal of methods in psychiatric research · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 25 Oct 2026
Completed2020 participants
NCT07913529
Time Course of Clozapine-associated Agranulocytosis Over 19 Years
No phaseEnded 25 Sept 2026
No phaseEnded 20 Sept 2026
Completed10 participants
NCT07446478
TIS for Improving Cognitive Impairment Associated With Schizophrenia
Phase 2Ended 16 Sept 2026
Completed149 participants
NCT07191483
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
No phaseEnded 24 Aug 2026
Phase 1Ended 3 Aug 2026
Completed107 participants
NCT06993662
The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.
No phaseEnded 31 Jul 2026
Completed6876 participants
NCT07571148
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
No phaseEnded 31 Jul 2026
Phase 3Ended 22 Jul 2026
Completed39 participants
2024-513222-30-00
Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
No phaseEnded 30 Jun 2026
Completed736 participants
NCT04007510
California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis
No phaseEnded 30 Jun 2026
Completed60 participants
NCT07917637
Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia
Phase 1Ended 26 Jun 2026
Phase 3Ended 24 Jun 2026
Stopped early1 participants
NCT05603104
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Reason given: The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.
No phaseEnded 15 Jun 2026
Phase 2Ended 11 Jun 2026
Completed307 participants
NCT07038876
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Phase 3Ended 8 Jun 2026
No phaseEnded 31 May 2026
Completed53 participants
NCT07043803
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
No phaseEnded 31 May 2026
Completed78 participants
NCT05985993
Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia
No phaseEnded 30 May 2026
Completed41 participants
NCT07364825
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
No phaseEnded 28 May 2026
Completed194 participants
NCT04951700
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
No phaseEnded 22 May 2026
Completed33 participants
NCT06410508
Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis
No phaseEnded 19 May 2026
Completed21 participants
NCT04867681
Study of the Impact on the Therapeutic Alliance of a Short Initial Psychoeducation Programme in Patients With Early Schizophrenia
No phaseEnded 30 Apr 2026
Phase 2Ended 27 Apr 2026
Completed20 participants
2024-511433-35-00
EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680
No phaseEnded 23 Apr 2026
No phaseEnded 22 Apr 2026
Completed30 participants
NCT06628323
Neuro-VR: Augmenting a Virtual Reality-based Therapy With Biofeedback for Auditory Hallucinations
No phaseEnded 17 Apr 2026
Completed28 participants
NCT06426134
Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS
No phaseEnded 15 Apr 2026
Completed284 participants
NCT04916626
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
- Early intervention versus treatment as usual for adolescents with first-episode psychosis: Protocol for the randomized OPUS YOUNG trial. · Contemporary clinical trials, 2026
No phaseEnded 1 Apr 2026
Phase 3Ended 25 Mar 2026
No phaseEnded 24 Mar 2026
Completed76 participants
NCT05100888
Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms
Phase 2Ended 23 Mar 2026
No phaseEnded 15 Mar 2026
Completed60 participants
NCT07917520
Mindfulness-Integrated Psychoeducation for Patients With Schizophrenia
No phaseEnded 11 Mar 2026
Completed40 participants
NCT07427485
Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study
- Cognitive rehabilitation with immersive virtual reality in schizophrenia: A randomized waiting list-controlled study. · Schizophrenia research. Cognition, 2026
No phaseEnded 25 Feb 2026
Phase 2Ended 25 Feb 2026
No phaseEnded 15 Feb 2026
No phaseEnded 5 Feb 2026
No phaseEnded 31 Jan 2026
Completed6 participants
NCT05169268
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
No phaseEnded 31 Jan 2026
Completed42 participants
NCT07609953
Cognitive Behavioral Therapy Added to Risperidone for Schizophrenia
Phase 2Ended 31 Jan 2026
Completed80 participants
NCT07575516
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone
No phaseEnded 31 Jan 2026
Completed50 participants
NCT07524868
Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients
No phaseEnded 31 Jan 2026
Completed425 participants
NCT06007105
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
No phaseEnded 31 Jan 2026
Completed44 participants
NCT07523256
Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
No phaseEnded 31 Jan 2026
Completed80 participants
NCT07541157
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
No phaseEnded 23 Jan 2026
No phaseEnded 23 Jan 2026
Completed65 participants
NCT05380583
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
No phaseEnded 23 Jan 2026
No phaseEnded 19 Jan 2026
Completed64 participants
NCT07643714
Effects of ACT-Based Psychoeducation on Caregivers of Individuals With Mental Disorders
Phase 2Ended 19 Jan 2026
Completed363 participants
NCT07550387
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
No phaseEnded 14 Jan 2026
No phaseEnded 13 Jan 2026
No phaseEnded 13 Jan 2026
Completed179 participants
NCT05863572
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
No phaseEnded 12 Jan 2026
Completed30 participants
NCT06003036
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
No phaseEnded 7 Jan 2026
Completed30 participants
NCT06993831
ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia
No phaseEnded 4 Jan 2026
Completed226 participants
NCT05461885
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
No phaseEnded 31 Dec 2025
Completed436 participants
NCT07818603
Screening and Monitoring of Mental Health in Educational Settings: Programme for Detection, Psychoeducation and Self-help
No phaseEnded 30 Dec 2025
Completed343 participants
NCT05030272
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
No phaseEnded 28 Dec 2025
Completed38 participants
NCT07512843
Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia
Phase 1Ended 23 Dec 2025
Completed110 participants
2025-521914-25-00
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants
Not medical advice. fetched 6 Nov 2026